It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Michael J. LaBarre net worth and biography

Michael LaBarre Biography and Net Worth

SVP of Halozyme Therapeutics

Dr. LaBarre brings to Halozyme more than 25 years of experience across all aspects of biopharmaceutical research and drug development, including strong expertise in chemistry, manufacturing, and controls (CMC), regulatory strategy and product development. Dr. LaBarre joined Halozyme in 2008 and has held leadership positions in product development, alliance management, research, and regulatory affairs during that time. He is currently responsible for providing scientific and technical leadership across all Halozyme programs and is the lead expert on Halozyme’s ENHANZE^® drug delivery technology.

Prior to Halozyme, Dr. LaBarre served as Vice President of Product Development at Paramount BioSciences, LLC, where he led CMC and research efforts for the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served from 1995 to 2006 in various research and development positions at Biogen Idec (formerly IDEC before the merger with Biogen in 2004), where he supported numerous IND and BLA submissions, including those for the commercial products RITUXAN^® and ZEVALIN^®. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. and he began his career at Hybritech in San Diego in 1992. Dr. LaBarre also taught chemistry laboratory for several years as an adjunct professor at Mesa Community College early in his career.

Dr. LaBarre received his B.S. in Chemistry from Southampton College of Long Island University and his Ph.D. in Chemistry from the University of Arizona.

What is Michael J. LaBarre's net worth?: The estimated net worth of Michael J. LaBarre is at least $7.95 million as of October 16th, 2024. Mr. LaBarre owns 173,756 shares of Halozyme Therapeutics stock worth more than $7,951,075 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. LaBarre may own. Additionally, Mr. LaBarre receives an annual salary of $843,890.00 as SVP at Halozyme Therapeutics. Learn More about Michael J. LaBarre's net worth.
How old is Michael J. LaBarre?: Mr. LaBarre is currently 60 years old. There are 2 older executives and no younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics is Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., President, CEO & Director, who is 61 years old. Learn More on Michael J. LaBarre's age.
What is Michael J. LaBarre's salary?: As the SVP of Halozyme Therapeutics, Inc., Mr. LaBarre earns $843,890.00 per year. There are 2 executives that earn more than Mr. LaBarre. The highest earning executive at Halozyme Therapeutics is Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., President, CEO & Director, who commands a salary of $1,820,000.00 per year. Learn More on Michael J. LaBarre's salary.
How do I contact Michael J. LaBarre?: The corporate mailing address for Mr. LaBarre and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on Michael J. LaBarre's contact information.
Has Michael J. LaBarre been buying or selling shares of Halozyme Therapeutics?: During the last ninety days, Michael J. LaBarre has sold $532,600.00 in shares of Halozyme Therapeutics stock. Most recently, Michael J. Labarre sold 10,000 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a transaction totalling $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $9,254,244.56. Learn More on Michael J. LaBarre's trading history.
Who are Halozyme Therapeutics' active insiders?: Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.
Are insiders buying or selling shares of Halozyme Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 174,881 shares worth more than $9,056,983.70. The most recent insider tranaction occured on October, 16th when SVP Michael J Labarre sold 10,000 shares worth more than $532,600.00. Insiders at Halozyme Therapeutics own 2.7% of the company. Learn More about insider trades at Halozyme Therapeutics.
Information on this page was last updated on 10/16/2024.

Michael J. LaBarre Insider Trading History at Halozyme Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2024	Sell	10,000	$53.26	$532,600.00	173,756
9/18/2024	Sell	10,000	$62.03	$620,300.00	173,756
8/21/2024	Sell	10,000	$61.75	$617,500.00	168,176
7/24/2024	Sell	10,000	$55.12	$551,200.00	168,176
5/22/2024	Sell	10,000	$45.38	$453,800.00	168,176
4/17/2024	Sell	10,000	$38.49	$384,900.00	168,176
3/12/2024	Sell	10,000	$41.64	$416,400.00	156,558
2/28/2024	Sell	10,000	$39.55	$395,500.00	156,558
12/12/2023	Sell	10,000	$39.63	$396,300.00	151,911
10/17/2023	Sell	10,000	$36.52	$365,200.00	151,911
9/19/2023	Sell	10,000	$39.10	$391,000.00	151,911
8/22/2023	Sell	10,000	$42.41	$424,100.00	151,911
8/22/2023	Sell	10,000	$42.41	$424,100.00	151,911
7/18/2023	Sell	10,000	$40.43	$404,300.00	141,911
6/21/2023	Sell	10,000	$36.00	$360,000.00	141,911
4/18/2023	Sell	10,000	$36.00	$360,000.00	141,911
2/27/2023	Sell	10,000	$49.55	$495,500.00	138,927
2/15/2023	Sell	10,000	$48.39	$483,900.00	143,477
1/17/2023	Sell	10,000	$50.46	$504,600.00	143,137
12/13/2022	Sell	10,000	$58.67	$586,700.00	153,137
11/15/2022	Sell	10,000	$54.13	$541,300.00	163,137
10/1/2021	Sell	29,450	$39.93	$1,175,938.50
7/1/2021	Sell	40,315	$45.70	$1,842,395.50
4/1/2021	Sell	28,689	$42.56	$1,221,003.84
3/1/2021	Sell	18,324	$45.81	$839,422.44	129,330
12/21/2020	Sell	12,000	$42.58	$510,960.00	123,400
11/20/2020	Sell	12,000	$38.76	$465,120.00	142,689
10/20/2020	Sell	12,000	$30.43	$365,160.00	146,800
9/21/2020	Sell	12,000	$26.91	$322,920.00	158,800
8/20/2020	Sell	12,000	$28.30	$339,600.00	170,800
7/20/2020	Sell	12,000	$29.01	$348,120.00	182,800
5/20/2020	Sell	21,387	$23.80	$509,010.60	197,574

Michael J. LaBarre Buying and Selling Activity at Halozyme Therapeutics

Halozyme Therapeutics Company Overview

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $45.76

$44.10

$46.20

50 Day Range

MA: $55.15

$42.57

$62.91

2 Week Range

Now: $45.76

$33.15

$65.53

Volume

1,875,025 shs

Average Volume

2,053,741 shs

Market Capitalization

$5.82 billion

P/E Ratio

15.15

Dividend Yield

N/A

Beta

1.29

Tesla Execs are Freaking Out

From Angel Publishing | Ad

Click here to get the details.

Michael LaBarre Biography and Net Worth

What is Michael J. LaBarre's net worth?

How old is Michael J. LaBarre?

What is Michael J. LaBarre's salary?

How do I contact Michael J. LaBarre?

Has Michael J. LaBarre been buying or selling shares of Halozyme Therapeutics?

Who are Halozyme Therapeutics' active insiders?

Are insiders buying or selling shares of Halozyme Therapeutics?